The LR3 designation refers to specific structural modifications that distinguish it from naturally occurring IGF-1, extending its activity and giving it different pharmacological characteristics
Come and try it out for yourself
If BPC-157 demonstrates efficacy and safety in properly designed human trials, I would be among the first to incorporate it
Peripheral effects Via the AMY2 and AMY3 receptors Cagrilintide acts peripherally: Slowing of gastric emptying , stronger than with GLP-1 Suppression of postprandial glucagon , helps control postprandial glycemic spikes Modulation of bone remodeling (via AMY3), a neutral effect, but clinically monitored Synergy with GLP-1 (the mechanistic basis of CagriSema) The main innovation is the complementarity with the GLP-1 pathway : GLP-1 suppresses appetite via the arcuate nucleus of the hypothalamus (POMC neurons, AgRP/NPY inhibition) Amylin suppresses appetite via the area postrema (CGRP-like neurons) Two independent centers, two independent mechanisms
Different than NAD, though, because if you're taking NAD by itself, not absorbed orally well at all